Chimeric Therapeutics (ASX:CHM) Announces $6.6 Million Placement to Advance Clinical Trials
Chimeric Therapeutics (ASX:CHM) announces a $6.6 million placement to fund key clinical trials in its cell therapy pipeline.
Category: Healthcare
Monash IVF Group (ASX:MVF) Updates FY25 Profit Guidance
Monash IVF Group (ASX:MVF) revises FY25 Underlying NPAT guidance to $27.5m, reflecting softer market conditions.
Noxopharm Limited (ASX:NOX) Raises $2.5 Million from Nyrada Share Sale
Noxopharm Limited (ASX:NOX) raised $2.5 million through a share sale to fund upcoming clinical trials and R&D initiatives.
Vitura Health Limited (ASX:VIT) Acquires Heyday Medical Clinic
Vitura Health Limited (ASX:VIT) through its Flora joint venture acquires Heyday Medical Clinic, enhancing its holistic healthcare network nationally.
Anatara Lifesciences (ASX:ANR) Announces Phase II GaRP-IBS Trial Results
Anatara Lifesciences (ASX:ANR) reports Phase II GaRP-IBS trial results, highlighting safety and significant symptom relief trends.
HITIQ Limited (ASX:HIQ) Announces Entitlement Issue to Raise up to $2.92 Million
HITIQ Limited (ASX:HIQ) launches a non-renounceable entitlement issue aiming to raise up to $2.92 million to expand manufacturing and USA operations.
Chimeric Therapeutics (ASX:CHM) Reports Positive ADVENT-AML Trial Results
Chimeric Therapeutics (ASX:CHM) reports that two of three patients achieved complete response in its ADVENT-AML Phase 1B clinical trial.
Epsilon Healthcare Limited (ASX:EPN) Announces Issue of $1M Loan Notes
Epsilon Healthcare Limited (ASX:EPN) issues loan notes to raise $1 million for operational expansion and diversification.
Mayne Pharma (ASX:MYX) Receives Court Approval for Acquisition Scheme
Mayne Pharma (ASX:MYX) receives Supreme Court approval for Cosette Pharmaceuticals’ acquisition scheme, leading to an upcoming shareholder vote.
Mesoblast (ASX:MSB) Receives 7-Year FDA Orphan Drug Approval for Ryoncil™
Mesoblast (ASX:MSB) secures 7-year FDA orphan-drug exclusivity for Ryoncil™ in treating pediatric SR-aGvHD, strengthening its IP protection.